# Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

> **NCT07645625** · PHASE4 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 261 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Early discontinuation of Pembrolizumab with or without Bevacizumab

## Key facts

- **NCT ID:** NCT07645625
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2030-05
- **Final completion:** 2039-02
- **Target enrollment:** 261 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645625, "Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*